Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755872 · ClinicalTrials.gov registry record · Phase 1
Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate
A Phase 1 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT00755872 is a Phase 1 study that has completed, run by Warner Chilcott. The registered enrollment target is 76 participants.
The verdict
NCT00755872, a Phase 1 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a randomized, open-label, multi-center, 4-treatment, 4-period crossover study. Approximately 72 healthy, surgically sterile or postmenopausal subjects will be enrolled and have urine collected over 72 hours following administration of risedronate for all 4 treatment periods).
Interventions
- DRUG Risedronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00755872
The ClinicalTrials.gov registry entry for NCT00755872 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risedronate is the first listed.
NCT00755872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00755872 about?
NCT00755872 is a clinical study titled "Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate". This is a randomized, open-label, multi-center, 4-treatment, 4-period crossover study. Approximately 72 healthy, surgically sterile or postmenopausal subjects will be enrolled and have urine collected over 72 hours following administration of risedronate for all 4 treatment periods).
What is the current status of trial NCT00755872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2007-11. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00755872?
The interventions under investigation include: Risedronate (DRUG).
Who is sponsoring clinical trial NCT00755872?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.